Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 16, 2024 04:30 ET | Source: Orion Oyj

Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer

ORION CORPORATION PRESS RELEASE 16 SEPTEMBER 2024 at 11.30 EEST Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46%...
August 14, 2024 16:01 ET | Source: Celcuity Inc.

Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update

Announced plan to initiate Phase 3 VIKTORIA-2 trial evaluating gedatolisib combined with fulvestrant plus a CDK4/6 inhibitor as first-line treatment for patients with HR+, HER2- advanced breast...
August 12, 2024 16:05 ET | Source: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

Initiated dosing of ORIC-944 in combinations with NUBEQA® (darolutamide) and ERLEADA® (apalutamide) in the ongoing Phase 1b trial for prostate cancer Entered into clinical trial collaboration and...
August 08, 2024 05:00 ET | Source: Orion Oyj

Orion Group Half-Year Financial Report January–June 2024

ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2024 8 AUGUST 2024 at 12:00 EEST Orion Group Half-Year Financial Report January–June 2024 Net sales totalled EUR 636.7 (January–June 2023:...
August 07, 2024 07:05 ET | Source: Celcuity Inc.

Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call

MINNEAPOLIS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
July 17, 2024 01:30 ET | Source: Orion Oyj

Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION17 JULY 2024 at 8.30 EEST Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen...
July 16, 2024 16:59 ET | Source: ORIC Pharmaceuticals

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients with mCRPC ORIC entered into clinical trial...
July 15, 2024 08:00 ET | Source: Oncternal Therapeutics

Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
June 12, 2024 11:34 ET | Source: Research and Markets

Metastatic Prostate Cancer Markets, Pipeline Analysis, Epidemiology Forecast and Competition Data; 2018-2034

Dublin, June 12, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Prostate Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ...
June 03, 2024 16:01 ET | Source: Celcuity Inc.

Celcuity To Participate in Jefferies Global Healthcare Conference

MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...